Roche said its T cell engager Lunsumio cleared a Phase 3 confirmatory trial in a slow-growing blood cancer, clearing the path for full approval and a broader label. The company’s bispecific targets are aimed at expanding treatment options as confirmatory data translate into regulatory review next steps for market authorization.